Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead

This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality of life.